NEW EMERGING CDMOs IN APAC
10 - 11 September 2025 | Singapore
Introduction
The Asia-Pacific (APAC) region has rapidly emerged as a strategic hub for biologics manufacturing, driven by growing demand, regional investments and technological advancements. Alongside established players, a new generation of Contract Development and Manufacturing Organizations (CDMOs) is rising, offering specialised capabilities in biologics, advanced therapies and integrated end-to-end services. This eBook highlights key emerging CDMOs that are shaping the future of biomanufacturing across APAC.
Year Established: 2020 Location / Headquarters: New Taipei City, Taiwan Core Focus: CDMO services for cell and gene therapy products, including CAR-T, iPSC-derived therapies, MSCs, and tissue-engineered products.
Key Highlights
- Operates a PIC/S GMP-compliant facility with over 24 cleanrooms
- Strategic collaboration with Hitachi Group to build advanced GMP-compliant manufacturing infrastructure
- Awarded “Emerging CDMO of the Year” at Asia-Pacific Biopharma Excellence Awards 2025
Year Established: 2014 Location / Headquarters: Boston, USA; Shanghai, China Core Focus: Full-spectrum biologics CDMO services, including microbial fermentation, mammalian cell culture, gene and cell therapy and ADCs.
Key Highlights
- Developed the world’s first and largest 30,000L stainless steel ultra-large bioreactor for mammalian cell culture production
- Operates GMP facilities in Shanghai, with additional R&D centers in Boston and San Francisc
- Recognized with the "Emerging CDMO of the Year" award at the Asia-Pacific Biopharma Excellence Awards 2025
Year Established: 2020 Location / Headquarters: Bangalore, Karnataka, India Core Focus: Contract Research, Development, and Manufacturing Organization (CRDMO) offering integrated services for small and large molecules, including discovery, development, and manufacturing of APIs, intermediates and formulations.
Key Highlights
- Operates USFDA-inspected cGMP facilities across India, the UK, and Mexico
- Specializes in peptides, high-potent APIs, mPEGs, steroids, carbohydrates, and flow chemistry
- Committed to sustainability goals, including becoming water-positive in 2023 and aiming for carbon neutrality by 2030
Year Established: 2019 Location / Headquarters: Nanjing, China; with facilities in Singapore, US, Netherlands and South Korea Core Focus: End-to-end CDMO services for biologics, including antibody discovery, cell and gene therapy (CGT), and recombinant protein drugs
Key Highlights
- Established the largest GMP plasmid facility and the first GMP manufacturing platform in China for circular plasmids, linearised plasmids, mRNA in vitro transcription (IVT-mRNA) and liposome nanoencapsulation (mRNA-LNP)
- Supported over 60 Investigational New Drug (IND) approvals globally since October 2017
- Assisted in advancing China's first CAR-T, TCR-T, mRNA vaccine and CRISPR programs to clinical trials
Year Established: 2013 Location / Headquarters: Yantai, Shandong Province, China Core Focus: Contract Development and Manufacturing Organization (CDMO) specialising in biologics, including monoclonal antibodies (mAbs), recombinant proteins, antibody-drug conjugates (ADCs) and bispecific antibodies.
Key Highlights
- Provides end-to-end services from gene sequencing, cell line development, process characterisation, conjugation optimisation, to cGMP commercial manufacturing of final drug products
- Operates multiple facilities, including the M1 facility built in 2015, a 270,000 square foot plant with upstream and downstream suites supporting high-scale manufacturing
Year Established: 2015 (as Richcore Lifesciences; rebranded to Laurus Bio in 2021) Location / Headquarters: Hyderabad, India Core Focus: Contract Development and Manufacturing Organisation (CDMO) specialising in animal-origin-free recombinant proteins, enzymes, and cell culture media for biopharmaceutical applications. Also expanding into sustainable biologics manufacturing.
Key Highlights
- Successfully expanded its portfolio from recombinant proteins to include a wide range of biopharmaceutical intermediates and active ingredients
- Pioneering animal-origin-free and chemically defined media products that support safer and more consistent bioprocessing
- Strong emphasis on sustainability with green manufacturing practices to reduce environmental impact
Conclusion
As demand for biologics and advanced therapies grows, these emerging CDMOs are rising to meet global needs with agility, innovation and regional expertise. From large-scale mammalian cell culture to cutting-edge cell and gene therapy services, the APAC region is proving to be a powerhouse in the next era of biomanufacturing.
BIOLOGICS CDMO ASIA 2025
Asia's Premier Event Exclusively for CDMO's!
📍Singapore 📆 10 - 11 September 2025
The 4th Biologics CDMO Asia 2025 is a prominent event that brings together key leaders in the contract manufacturing sector to exchange successful case studies, address challenges and opportunities, and explore potential partnerships. It is also the only conference in the region that is exclusively focused on Contract Manufacturing in the APAC region.
350+ Attendees
180+ Organisations
40+ Expert Speakers
2025 SPEAKERS
Christopher Pawlak
External Manufacturing Lead, Bayer, Switzerland
Daniel Hurni
Director Manufacturing Network Strategy and Business Intelligence, Bristol Myers Squibb, Switzerland
Hu Jun
Vice President, Head of Client Enabling Center of Excellence & Head of Singapore Site Management at WuXi XDC, Singapore
Sudeep Srivastava
Senior Vice President, Biological E. Limited, India
Jimmy Chang
CEO, TaiMed Biologics, Taiwan
Liu Song Yun
Quality Manager, External Manufacturing, GSK, Singapore
Julio Lin
Vice President, Blue Blood Biotech, Taiwan
Jennifer Kuan
VP of Taiwan Operations, Bora Biologics, Taiwan
Kamyar Sadri
Former Regional Digital, Data & IT Lead, South East Asia, Novo Nordisk, Singapore
Akhil Prakash Chincholikar
Head R&D Project Management, Naprod Life Sciences, India
Warren Chan
Dean of the College of Engineering, Nanyang Technological University (NTU), Singapore
Lucas Chan
Visiting Senior Investigator and Advisor, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Bi Xuezhi
Senior Principal Scientist I & Group Leader, Protein Analytics, A*STAR Bioprocessing Technology Institute (BTI), Singapore
Andy Tan
Principal Scientist and Group Leader, Immune Cell Manufacturing, A*STAR Bioprocessing Technology Institute (BTI), Singapore
Zach Pang
Group Leader, Analytical Science & Technology (Bioprocess Data Integration), A*STAR Bioprocessing Technology Institute (BTI), Singapore
Share With Your Network
